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ABSTRACT
Diabetes is one of the most prevalent, costly, and debilitating diseases in the world. Although traditional
insulin therapy has alleviated the short-term effects, long-term complications are ubiquitous and harmful.
For these reasons, alternative treatment options are being developed. This review investigates one ap-
pealing area: cell replacement using encapsulated islets. Encapsulation materials, encapsulation methods,
and cell sources are presented and discussed. In addition, the major factors that currently limit cell
viability and functionality are reviewed, and strategies to overcome these limitations are examined. This
review is designed to introduce the reader to cell replacement therapy and cell and tissue encapsulation,
especially as it applies to diabetes.
INTRODUCTION
D IABETES MELLITUS, one of the most prevalent and de-structive diseases in the world, affects more than 150
million individuals. It is the sixth leading cause of death in the
United States, contributing to more than 200,000 deaths each
year. In addition to the fatality rate, the cost associated with
this disease is in excess of $105 billion annually in the United
States, and one in four Medicare dollars goes toward diabetes
and its associated complications.1 Diabetes is also becoming
more prevalent; the incidence of diabetes has increased 61%
since 1991. The increasing prevalence, as seen in Figure 1,
and the tremendous cost of diabetes are driving innovative
research at the frontiers of medicine and bioengineering,
warranting a review of the history, current status, and near-
term outlook for diabetes treatment.
In 1921, when Fredrick Banting and Charles Best discov-
ered insulin, many believed that the deleterious effects of
diabetes would be eliminated. Unfortunately, the availability
of insulin was not sufficient to meet the demand, but as pro-
duction of insulin increased, there was renewed optimism that
diabetes could be curtailed.2 Although insulin therapy has
significantly reduced the immediate risks of diabetes, the
chronic effects of diabetes are increasingly problematic. With
the use of insulin therapy, diabetic patients can live longer, but
chronic complications prevail as the primary cause of mor-
bidity and mortality. These complications include cardio-
vascular diseases, renal failure, amputations, and blindness.
Studies have shown that intensive control of hyperglycemia,
through strict dietary adherence and precise insulin therapy,
can reduce the occurrence or progression of diabetic com-
plications;3 however, tight control of blood glucose levels
using existing treatments is difficult.4 Consequently, tremen-
dous resources are being directed toward developing im-
proved treatment options for individuals with diabetes.
Current therapies for diabetic patients at early stages in-
clude insulin injections, dietary restrictions, and exercise,
whereas therapies for diabetic patients with severe symptoms
involve transplantation of the entire pancreas (organ trans-
plantation) or of purified islets (cell transplantation). The
complications associated with transplantation, such as sur-
gical morbidity and chronic immuno-suppression, however,
must be considered and compared with the potential ben-
efit of improved glucose metabolism. Several advanced
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technologies, such as enclosed insulin-delivery systems and
gene therapy, have also been developed to more effectively
treatdiabetes,5offeringalternativestothetraditionaltreatments
of insulin injections and diet. The reader is referred to sev-
eral recent review papers on diabetes treatment through gene
therapy5–9 and closed-loop insulin-delivery systems,10–14
allowing this review to focus primarily on a promising bio-
engineering approach, islet encapsulation, for restoring nor-
moglycemia through islet transplantation.15
ISLET TRANSPLANTATION
Islet transplantation involves the transfer of healthy islet
cells from a donor to the diabetic patient. The advantages of
islet transplantation over whole-organ, or pancreatic, trans-
plantation are the elimination of major surgery, the reduced
mass at transplantation time (beta-cells are about 1% of the
total pancreas weight), and the potential storage of donor
cells by cryopreservation. Although islet transplantation has
been shown to control glucose levels successfully, there are
several drawbacks involved with this procedure. The major
obstacles to islet transplantation are the availability of islets
and the maintenance of islet functions such as cell growth
and survival. For instance, islet cells, unlike other cell types,
cannot be expanded in vitro to provide sufficient cells for
transplantation. Islet cells also tend to clump together, caus-
ing the core cells to die because of the limitation of nutrient
transport to the aggregate center, which subsequently re-
duces cell functional replacement. Another obstacle to islet
transplantation is the host rejection of implanted islets. Thus,
patients are required to take lifelong immuno-suppressive
drugs to overcome the rejection of transplanted islet cells.
This raises the question of whether islet transplantation is
preferable to continuous insulin treatment.
One approach to overcome these obstacles is islet encap-
sulation.16,17 Islet encapsulation uses an immuno-protective
biomaterial to create a permselective membrane around a
group of islet cells. A device of this type is often referred to
as a bioartificial pancreas. The membrane allows the islets to
regulate blood glucose levels through insulin release while
excluding, based on size, the larger proteins and cells of the
immune system. Thus, encapsulation is designed to limit,
and ideally eliminate, an immunological response to the
non-host islet cells. Isolation of the islet cells from the hu-
man immune system may also make xeno-transplants pos-
sible, eliminating the supply problem that exists. This article
will present the materials and cells used, methods that have
been employed, and prospects for future developments with
regard to islet cell encapsulation.
ENCAPSULATION MATERIAL
The encapsulation material must perform two vital
functions—it must isolate the encapsulated islet cells from
the immune system, and it must allow the transport of small
molecules such as glucose and nutrients into the islets—in
addition to permitting diffusion of insulin and waste prod-
ucts. The purpose of encapsulation is to reduce rejection of
the insulin-producing cells by the immune system. However,
if immuno-isolation is achieved at the cost of critically hin-
dered mass transport of insulin, glucose, oxygen, and other
necessary molecules, then cell death will occur, and the
device will fail. Even if the molecular-weight cutoff is ap-
propriate for these first two critical parameters, host protein
adsorption and fibrous encapsulation could cause failure of
the device. There are several important constraints on the
material properties of the encapsulating matrix.
Several materials, including alginate and polysulphone
(PS), have shown promise in sequestering the insulin-
producing cells from immune-effector cells, the complement
system, and immunoglobulins.18–21 Of these materials, al-
ginate, a natural material derived from kelp, has been the
most widely used, and islet capsules produced from this
material are in clinical trials.22,23 Furthermore, various ma-
terials such as poly(ethylene glycol) (PEG) and poly-L-
lysine (PLL) have been incorporated into alginate to reduce
plasma adsorption and to form semi-permeable membranes
that permit nutrient and oxygen transport but limit immu-
nogenic reactions.24 For example, Cui et al. demonstrated
that grafting PEG chains onto alginate capsules increased
in vivo viability of islet cells.25 PLL and poly-l-ornithine
(PLO) have also been used to coat alginate islet beads to
improve islet survival and to allow rapid removal of the
systems.19–21,26
In addition to alginate, PS has also been pursued as a
possible encapsulation material. PS has a long history of use
in renal dialysis and is readily fabricated as hollow fibers
with a tight molecular-weight cutoff. Because PS is hydro-
phobic and adsorbs large amounts of insulin, work has been
done to modify PS to render it more hydrophilic, allowing
better insulin diffusion. However, blending PS with poly-
vinylpyrrolidone or sodium-dodecyl-sulfate interfered with
proper islet function such as glucose-induced insulin re-
lease.27 On the other hand, hydroxy-methylated PS shows
considerable promise as an encapsulation material because it
does not limit the diffusion of insulin or alter insulin secre-
tion of macroencapsulated islets.27 A combined ‘‘macroen-
capsulation’’ approach of filling PS hollow fibers with islet
cells in an alginate matrix has shown promising results in
diabetic rats up to 20 days.28
In addition to alginate and PS, other materials such as
PEG, dimethylaminoethyl methacrylate–methyl methacry-
late copolymer, and poly(vinyl alcohol) have been used for
islet encapsulation. Some of these materials, and the meth-
ods associated with their formation, are less than ideal be-
cause of reduced viability and functionality of the islet cells
due to polymer biodegradation, permeability of the capsules,
fragility, and limited surface area.29 Additionally, a few
hydrogels use photo-initiation in the formation of the hy-
drogel, which may damage the encapsulated cells.30 Further-
590 BECK ET AL.
more, amniotic membranes, nano-porous micro-systems,
and silica have been evaluated as possible materials for
encapsulation.31–33 It has also been proposed that a refillable
synthetic extracellular matrix (ECM) could be constructed
using a copolymer of poly(N-isopropyl-acrylamide) and
acrylic acid.34 A bioartificial pancreas of this type would
allow for infusion of additional islet cells if necessary.
Several materials have produced positive results, which
illustrates the great promise of islet encapsulation. However,
the properties and manufacturing methods of somematerials
may limit their use in the future. One limitation of all of these
materials is their inability to prevent cytokine transfer across
the membrane.32 This may not be crucial in autografts or
allografts but would be an essential characteristic of an en-
capsulation material for use in xenografts. Selection of en-
capsulation material is vital, and as aforementioned, there
are numerous materials being evaluated to determine the
optimal materials and processing methods for islet encap-
sulation.
CELLS USED FOR ENCAPSULATION
The Islets of Langerhans are groups of cells in the pan-
creas that comprise four different cell types that produce the
following hormones: glucagons (a cells), insulin (b cells),
somatostatin (d cells), and pancreatic polypeptide (g cells).
Like many terminally differentiated cells, pancreatic
cells, especially b cells, cannot be grown in vitro to provide
sufficient cell mass for cell replacement. As a result, current
islet transplants are dependent on allograft donors.8,18,35,36
Encapsulation of allograft islet cells must increase their
survivability and functionality as well as reduce the need for
immune suppression. In addition to improving allograft
treatments, islet encapsulation presents the possibility of
increasing the availability of donor cells by making xeno-
grafts and other cellular transplants possible.
Although there are several viable cell sources for islet
encapsulation, human islet cells are an ideal choice for is-
let transplants. Recently, the first successful living-donor
islet transplantation took place in Japan.37 Unfortunately,
even with the advent of living-donor transplantations, the
demand will still be far greater than the supply for the same
reasons that the demand for kidney transplants is still much
higher than the supply. To overcome the limited supply of b
cells, various sources for new b cells have been investigated,
including embryonic stem cells, adult stem cells, immortal
islet cell lines, and xenografts.38
Embryonic stem cells
Because the mature islet cells do not readily divide, there
is great interest in differentiating embryonic and adult stem,
or precursor, cells into insulin-producing cells.39–44 Re-
cently, studies have succeeded in coaxing embryonic stem
cells to produce insulin.45,46 The cells were able to assemble
into 3-dimensional clusters, similar to those in vivo, and
maintained pancreatic function, including glucose-induced
insulin release. Factors used for stem cell differentiation
include signals from blood vessels such as vascular endo-
thelial growth factor A (VEGF-A) and fetal soluble factors,
which play an important role in the pancreatic differentia-
tion of embryonic stem cells.46–50 Additionally, undiffer-
entiated embryonic stem cells are genetically engineered
with b cell genes such as Nkx6.1 to obtain insulin-secreting
cells.51,52
FIG. 1. Prevalence of diabetes in the United States; 1990, 1995, 2001.
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Tissue progenitor/stem cells
Insulin-producing cells can also be generated from adult
stem cells as well as from embryonic stem cells. For instance,
neural stem cells have demonstrated the ability to differen-
tiate into cell clusters and to release insulin in response to
glucose, similar to islets.53,54 Adult spleen cells also have
been found to restore normoglycemia in diabetic mice.55
Although the adult stem cells lack the proliferative cap-
abilities of embryonic stem cells, they may be safer because
they would reduce the risk of uncontrolled proliferation
in vivo, which might lead to cancer later.18 In addition, adult
stem cells may make autologous cell transplants possible.
Islet cell lines
Because of the limited availability, difficulty, and ex-
pense of the isolation and differentiation of stem cells, is-
let cell lines have been explored as alternative cell sources
for islet transplantation. Immortalized cell lines from en-
docrine precursor cells of the human pancreas, using retro-
viral vectors expressing multiple dominant oncogenes, have
been developed to provide unlimited cell quantities for islet
transplantation to treat diabetes.41,56 To address the prob-
lems that transformed cells grow indefinitely, develop large
multi-cellular clusters, and force the encapsulated construct
to expand and eventually rupture, growth-regulated cell
lines have been generated by integrating tetracycline-off or
-on operon systems to allow cell growth regulation upon
exposure to tetracycline or its derivatives.18,57–59 Further-
more, the development of surrogate non-endocrine cells
genetically modified to secrete insulin may provide an al-
ternative source of cells that can regulate blood glucose
levels.60–62
Xenografts
In addition to stem cells and cell lines generated from hu-
mans, islets isolated from other species are another source for
b cell replacement.63 Porcine islets are an attractive option for
xeno-transplantation because of the high number of isolated
cells and the ability for genetic modification.63 Before re-
combinant insulin–producing Escherichia coli, porcine in-
sulin was often used in the treatment of diabetes. This
suggests that, for most individuals, porcine insulin would
effectively control blood glucose levels. One major draw-
back of xeno-transplantation is the need to use immuno-
suppression to prevent the destruction of pig islets by
immunological processes when they are exposed to human
blood. To protect islets from immune-mediated destruction,
PEG derivatives have been used to modify the surface of
adult porcine islets to provide an immuno-protection.29,64
Results from these studies have found that modification of
porcine islets using PEG derivatives demonstrated signifi-
cant in vitro and in vivo cyto-protection against immune
reactions, potentially precluding the need for cell-mass en-
capsulation.
Despite the potential of xenografts, there are several
major problems with using pig donors for islet transplanta-
tion. First, many individuals are opposed to this develop-
ment, and some individuals may eschew treatment involving
the use of cells derived from animal parts because of con-
flicts with their religious beliefs.65 Some are also against the
use of trans-species islet transplants because of the fear of
viral infection, particularly retroviruses.36,61 Viral infection
is a risk to the general population, not just those who receive
xenografts. For this reason, federal approval of xenografts
presents a unique challenge. Furthermore, encapsulation of
islets using a variety of biocompatible materials to avoid the
hyper-immune response to xenografts has failed to maintain
islet viability and secretory response.63 It is unlikely that
xenografts will be widely used in clinical applications until
these problems are overcome. Thus, insulin-producing cells
derived from stem cells present a promising alternative
posing less inherent risk.
METHODS OF ENCAPSULATION
There are three general encapsulation schemes that have
been studied for islet transplantation. These include intra-
vascular macrocapsules, extravascular macrocapsules, and
microcapsules. In each case, a permselective membrane is
used,with themolecular-weight cutoff dictating the immuno-
protective properties of the immuno-barrier. Membrane
chemistry and geometry are important aspects because they
influence mass transport across the membrane, biocompat-
ibility, and encapsulated cell viability.
An intravascular implant (Fig. 2A) is a perfusion chamber
designed to be directly connected to the vascular system of
the host via an arteriovenous shunt.66,67 In this system, blood
flows through the lumen of the hollow fibers. Thus, the islets
are in close proximity to the blood while being protected by
the membrane. The design of this device provides better
mass-transfer rates, which in turn augments transport of
nutrients and oxygen to the islets using convective blood
flow. Intravascular devices, however, have seen little suc-
cess because of the risk of damaging a blood vessel during
surgery and the formation of blood clots at the entrance and
exit regions of the device.18
Macroencapsules (Fig. 2B) contain a large mass of islet
cells within a diffusion chamber. Macroencapsulation de-
vices are usually formed from spun coat membranes or spun
drawn hollow fibers. Fiber diameter is an important factor to
be considered when hollow fibers are used for encapsulation.
A large-diameter fiber can result in a shorter overall length
but can lead to nutrient diffusion limitations, thereby causing
a central core of dead cells or necrotic tissue. In contrast, a
small-diameter fiber can improve the transport of nutrients,
but it can result in an extremely long fiber length, thereby
increasing the potential breakage and making implantation
more difficult. Extravascular macrocapsules can be im-
planted in the peritoneal cavity as well as subcutaneously.68
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One advantage of extravascular macrocapsules is that they
can be implanted and retrieved with minimal risk. However,
their major drawback is the limitation of oxygen diffusion
and nutrient transport, which dampens islet cell functions,
including viability.18
Microencapsulation (Fig. 2C) is the encapsulation of sin-
gle islets or small groups of islets. These capsules are usually
spherical in shape.69 Several methods have been used in
the production of islet microcapsules. These include double
emulsion, photopolymerization, micro-machined nanopo-
rous microsystems, and electrified coaxial liquid jets.32,70,71
Microcapsules offer the advantage of increased oxygen and
nutrient transport due to the large surface area–to-volume
ratio. The primary drawback of microencapsulation is the
difficulty in removing the implants if necessary. The debate
between macro- versus microencapsulation is an ongoing
dispute, and neither technique has demonstrated clear supe-
riority over the other.
FACTORS INFLUENCING SURVIVABILITY
AND FUNCTIONALITY
Although islet cell transplantation is promising, the re-
search has not progressed as quickly as was anticipated a
decade ago. This is due, in part, to limited reproducibility of
successful trials, as well as to the low survival rates and
impaired functions of encapsulated islet cells. The primary
causes of failure include hypoxia, limited diffusion at the
transplantation site, biocompatibility of the encapsulating
material, and insufficient immuno-protective properties of
the immuno-barrier.72
Hypoxia
Hypoxia is a major limitation in islet cell therapy because
islet cells need abundant amounts of nutrients and oxygen to
function properly. Normal pancreatic blood flow ensures
that islet cells, in their native physiological environment,
receive sufficient quantities of nutrients and oxygen.17,73,74
Conversely, hypoxia can occur in transplanted islet cells be-
cause of limited diffusion through a permselective mem-
brane. Hypoxia is most severe in areas furthest from the
oxygen supply. In intravascular grafts, hypoxia most readily
occurs at the perimeter of the device, whereas in extravas-
cular macrocapsules and microcapsules, hypoxia is most
problematic at the center of the cell mass.
Several methods have been investigated to reduce hyp-
oxic stress in islet encapsulation. Heat shock, ischemic
preconditioning, and stimulation of Bcl-2 and Bcl-xL before
implantation may reduce the initial, but not long-term,
hypoxic stress.75–77 There are also several proposed mo-
dalities for reducing chronic hypoxic stress. One proposed
modality is the use of Brockman bodies. Brockman bodies
are islet-like cells derived from tilapia fish accustomed
to living in hypoxic water and therefore able to withstand
low levels of oxygen.78 Pre-vascularization of the implant
site, or of an implant matrix, may also decrease hypoxia.79
Factors that increase vascularization, such as VEGF, can be
used to reduce hypoxic stress.80 Two other possibilities in-
clude genetic modification of insulin-producing cells and
the production of smaller microcapsules. For instance, genes
for hypoxia resistance could be transfected into insulin-
producing cells, increasing the ability of the cells to with-
stand hypoxic conditions. Finally, the formation of smaller
capsules will increase the surface-to-volume ratio, thereby
reducing the distance the oxygen must diffuse to reach the
center of the cell mass.
Transplantation site
It has been shown that the implantation site plays an im-
portant role in the hypoxic conditions, as well as the biocom-
patibility and survival of islets. For example, transplantation
into the peritoneum exacerbates hypoxic conditions because
oxygen is carried through the peritoneal cavity by passive
diffusion only.81 This passive transport also limits the rate of
insulin delivery from the islets, which hampers insulin se-
cretory responses.81 The result is that 200% to 400% more
islets must be implanted when the peritoneum is used as the
transplant site.82 Additionally, the peritoneum site is proin-
flammatory for implantation of alginate-encapsulated pig
islets, whereas kidney subcapsular and subcutaneous spaces
FIG. 2. Three schemes for encapsulating islet cells. (A) Intravas-
cular implant, (B) macroencapsulation, (C) microencapsulation.
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improve biocompatibility and islet viability.83 The liver has
also been investigated as a possible transplant site for islet
microcapsules.84 It may be possible to transplant the islet
microcapsules through an intra-portal injection, eliminating
the need for surgical implantation of the encapsulated is-
lets.85,86 For these reasons, many researchers are investi-
gating extra-peritoneal sites for the transplantation of islet
cells.
Material biocompatibility
Biocompatibility of the encapsulation material is also
vital for proper in vivo function of the encapsulated islets. It
has been shown that survival rates of encapsulated islets for
allografts and autografts are similar.87 This would suggest
that immune responses are not the only cause of failure. In
fact, insufficient biocompatibility of the membrane leads to
non-specific protein adsorption and fibrotic overgrowth of
the capsules, which results in necrosis.87–91 Physical or
chemical imperfections can cause necrosis, although phys-
ical imperfections account for fewer than 5% of these
cases.72 It is important that the material selected for encap-
sulation be highly biocompatible. Thus, several strategies
have been developed to improve the material biocompati-
bility. Of those, the addition of PEG chains to any encap-
sulation material will improve the biocompatibility of the
membrane by reducing non-specific protein adsorption.92
The biocompatibility of alginate can also be increased
through the removal of impurities from crude alginate.19
Immuno-protection properties
In addition to hypoxia and biocompatibility, the immuno-
protective properties of the immuno-barrier are also impor-
tant for the islet encapsulation process. Even in autografts,
immune protection is necessary, because in type I diabetes,
the immune system is responsible for the destruction of
the original b cells. Yet immune protection is more vital in
allografts and especially in xenografts. When properly se-
lected, the encapsulation material effectively sequesters the
islet cells from the large molecules of the immune system,
such as cells and antibodies. However, small molecules
produced by the islets can attract macrophages, especially in
xenografts, through chemotaxis.93 Chemotaxis may lead to
fibrosis, a process whereby the host seeks to isolate the
‘‘foreign device’’ by walling it off with proteins and other
materials. It has been shown that chemotaxis alone (without
the involvement of hypoxia or biocompatibility) can lead to
damage of the encapsulated islets.81 Chemoattractants, such
as cytokines, can activate macrophages, which in turn pro-
duce nitric oxide.94,95 Nitric oxide is small enough to diffuse
through the immuno-barrier and damage the islet cells.20
Therefore, several strategies have been developed to pro-
tect islets from nitric oxide–induced cellular damage. These
strategies include co-encapsulation (with erythrocytes or
Sertoli cells), addition of hemoglobin, and genetically en-
gineering islet cells that are resistant to the deleterious ef-
fects of nitric oxide.96–102
ADDITIONAL STRATEGIES TO INCREASE
ISLET CELL SURVIVAL AND FUNCTION
In the previous sections, several methods to increase the
survivability and functionality of the encapsulated islets have
been presented. These includemethods for reducing hypoxia,
selection of graft type (vascular, macro, or micro), selection
of transplantation site, biomaterial selection and processing,
and methods of increasing the immuno-protective properties
of the immuno-barrier. To prevent islet necrosis and induce a
longer survival rate and subsequent functional duration of a
bioartificial pancreas, several additional strategies have been
investigated. These strategies include the use of biological
factors, surface modification of islet cells, novel methods of
encapsulation, and ECM mimicry.
Several biological factors such as glucagon-like peptide-1,53
VEGF,27,103–106 and hepatocyte growth factor/scatter107,108
can be used to stimulate islet function. Other factors can also
be used to create a more-conducive environment for trans-
plantation. Many factors, such as VEGF, can increase vas-
cularity at the transplantation site, thus increasing diffusion
rates. These factors are incorporated with the encapsulated
materials or delivered with islets at transplantation to en-
hance the functionality of islets.
It has also been proposed that surface modification, rather
than encapsulation, may be sufficient to protect islets from
host responses. This would create excellent diffusion rates,
but it is unclear whether surface modification would provide
suitable immuno-protection. Conjugating PEG onto the islet
surfaces appears to increase islet cell survival in vivo, but the
best results required the synergistic effects of cyclosporine A
(a common immunosuppressant).109 Although PEGylation
of islet cells improves cell survival, it is unlikely that it will
prove effective in eliminating the need for immune suppres-
sion and would certainly be inadequate for xenotransplants.
Another approach to improving islet survival and function
is to revisit the encapsulation paradigm. A novel and prom-
ising encapsulation method employs the use of a construct
similar to a dialysis cartridge.116 A bioartificial pancreas
constructed in this manner would provide greatly increased
diffusion rates. It would also allow for the device to be ex-
planted if necessary. Although the first-generation device of
this design was tested extracorporeally, it is expected that
future experiments will involve intravascular implanta-
tion.116 Despite some drawbacks, namely blood clotting, the
preliminary results are promising.110
Although these different strategies may increase islet cell
survival and function, it is important to note that the inter-
actions between cells and their environment (integrin/ECM
interaction) also play an important role in maintaining islet
cell survival and function. Integrin/ECM interactions have
been shown to affect islet cell adhesion, proliferation, and
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differentiation. For example, avb3 and avb5 regulate adhesion
and differentiation of putative endocrine progenitor cells.111
The integrins, specifically a3b1 and a6b1, also regulate in-
sulin secretion in part.86,112,113 Additionally, islets cultured
on surfaces treated with anti-b1 or anti-a1 antibodies show
an increase in cell survival and glucose-stimulated insulin
secretion.53,114–116 In addition to the use of integrin antibod-
ies, ECM mimicry can be accomplished through incorpora-
tion of other ECM proteins and peptides.
It has been demonstrated that culturing islet cells on
ECM-like surfaces increases islet survival and function. For
instance, glucose-stimulated insulin secretion is greaterwhen
islets are cultured on surfaces treated with ECM molecules
suchas collagen type Ior IV, laminin, fibronectin, or arginine-
glycine-aspartate (RGD) peptides.53,114–116 These findings
indicate that incorporation of these ECM factors on the sur-
face of the encapsulationmaterial may improve islet survival
and function. The exploitation of integrin/ECM interac-
tions may also prove to be a vital element in creating a viable
bioartificial pancreas.
Mimicking thepancreaticmatrixmembrane through incor-
poration of ECM molecules may be another means of in-
creasing islet cell survival and function. Our preliminary
studies indicated that islet cells adhered preferentially to
cell-culture (polystyrene) surfaces coated with collagen IV
(Fig. 3) and other molecules such as RGD, anti-a1, and anti-
b1 (results not shown) in a dose-dependent manner. Of the
molecules studied, collagen IV, anti-a1, and anti-b1 appear
to have the greatest effect on islet cell adhesion (Fig. 4).
Passive absorption of collagen IV onto PS and PS with
polyvinyl pyrrolidone membranes also induced islet cell
adhesion (Fig. 5). However, this induction was not as sub-
stantial as those seen on the polystyrene surfaces. Future
FIG. 3. Collagen IV enhanced the adhesion of islet cells in a
dose-dependent manner. Various concentrations of collagen IV
were used to coat the cell culture surfaces, and islet cell adhesion
was determined using PicoGreen deoxyribonucleic acid (DNA)
assays. Results are presented as mean standard error of the mean
(n¼ 6), and * denotes significant difference compared with con-
trol samples (cell culture surfaces without coating).
FIG. 5. Collagen IV enhanced the capture of islet cells on the
surfaces of polysulfone (PS). Collagen IV (5 mg/cm2) was used to
coat the surfaces of PS and PS with polyvinyl pyrrolidone (PVP)
membranes. After seeding for 4 h, islet cell adhesion on each
surface was determined using PicoGreen deoxyribonucleic acid
(DNA) assays. Results are presented as mean standard error of
the mean (n¼ 6), and * denotes significant difference compared
with control samples (cell culture surfaces without coating).
FIG. 4. Extracellular matrix molecules and integrin antibodies
enhanced the capture of islets cells on the modified surfaces. Op-
timal concentrations of arginine-glycine-aspartate peptides (10mg/
cm2), collagen IV (5 mg/cm2), alpha1 antibodies (1.2mg/cm2), and
beta1 antibodies (0.15 mg/cm2) were used to coat the cell culture
surfaces, and islet cell adhesion was determined using PicoGreen
deoxyribonucleic acid (DNA) assays. Results are presented as
mean standard error of the mean (n¼ 6), and * denotes signif-
icant difference compared with control samples (cell culture sur-
faces without coating).
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work should include additional incorporation techniques, for
example, cross-linking or layer-by-layer surface modifica-
tion to improve the binding of collagen IV to PS. Further
studies to assess other islet cell functions, including glucose-
stimulated insulin release, will help to determine the efficacy
of collagen IV incorporation.
CONCLUSIONS AND OUTLOOK
Islet encapsulation is designed to overcome two major
obstacles to traditional islet transplantation: inadequate sup-
ply of islet cells and the need for patient immune suppression.
The creation of a clinically successful bioartificial pancreas
will require advances in several areas. Advances in bioma-
terials, cell sources (including stem cells), genetic engineer-
ing, growth factor delivery, and ECM mimicry will provide
new and valuable tools in the quest to create a viable bio-
artificial pancreas.
Perhaps no area of cell therapy has been more thoroughly
studied than islet transplantation. This presents uniqueoppor-
tunities and challenges. It is vital that collaboration and data
analysis efforts increase. This work is already underway; in
2004 the Collaborative Islet Transplant Registry (CITR) was
created. ‘‘The mission of CITR is to expedite progress and
promote safety in islet/beta-cell transplantation through the
collection, analysis, and communication of comprehensive
and current data on all islet/beta-cell transplants performed
in North America.’’117 The CITR is one example of how
collaborative efforts are being devoted to islet encapsula-
tion; however, these efforts must be expedited.
Despite the challenges of islet encapsulation, the outlook
is positive. The groundwork has been laid in laboratories and
clinical trials. The cost and limitations of current treatments
provide the motivation for modern technologies and novel
strategies. Advances in various fields such as lithography
and biomimetic materials already provide the necessary
tools for islet encapsulation. It is expected that, before the
close of this decade, a clinically successful bioartificial pan-
creas will be created. Clinical success will not only benefit
millions of individuals with diabetes, but will also provide a
road map for future bioartificial organs, including treatments
for cancer, liver failure, hemophilia, Parkinson’s disease,
muscular dystrophy, and heart diseases.
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